EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia

Tony Marchand iD, Cédric Pastoret iD, Gandhi Damaj, Angélique Lebouvier, Charles Herbaux iD, Aline Moignet, Miguel Pavlosky, Astrid Pavlosky iD, Anaise Blouet, Martin Eloit, Vincent Launay, Pierre Lebreton und 5 weitere

British Journal of Haematology · 2024-09 · 205 (3) · 915-923

DOI: 10.1111/bjh.19476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 19.04.2024. Verfasst von Tony Marchand und 16 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France. Hauptthemen laut MEDLINE: Nitriles, Pyrazoles, Pyrimidines, Leukemia, Large Granular Lymphocytic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Large granular lymphocytic (LGL) leukaemia is a rare chronic lymphoproliferative disorder characterized by an expansion of cytotoxic T or NK cells. Despite a usually indolent evolution, most patients will require a treatment over the course of the disease because of cytopenia or symptomatic associated autoimmune disorders. First‐line treatment is based on immunosuppressive agents, namely cyclophosphamide, methotrexate and ciclosporin. However, relapses are frequent, and there is no consensus on the management of relapsed/refractory patients. The implication of the JAK/STAT pathway in the pathogenesis of this disease has prompted our group to propose treatment with ruxolitinib. A series of 21 patients who received this regimen is reported here. Ten patients (47.6%) were refractory to the three main immunosuppressive drugs at the time of ruxolitinib initiation. Ruxolitinib yielded an overall response rate of 86% ( n = 18/21), including 3 complete responses and 15 partial responses. With a median follow‐up of 9 months, the median response duration was 4 months. One‐year event‐free survival and 1‐year overall survival were 57% and 83% respectively. Mild side effects were observed. Biological parameters, notably neutropenia and anaemia, improved significantly, and complete molecular responses were evidenced. This study supports ruxolitinib as a valid option for the treatment of relapsed/refractory LGL leukaemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitrilesPyrazolesPyrimidinesLeukemia, Large Granular LymphocyticHumansFemaleMaleMiddle AgedAgedAged, 80 and overAdultRecurrenceTreatment Outcome

Stichwörter der Autor:innen

T‐cell lymphomachronic T cell leukaemiaclinical studieslymphoproliferative diseasemolecular biology

Substanzen

NitrilesPyrazolesruxolitinibPyrimidines

Autor:innen und Institutionen

  • Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
  • Université de Rennes, Rennes, France.
  • UMR 1236, Rennes University, INSERM, Établissement Français du Sang Bretagne, Rennes, France.
  • Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.
  • Institut d'Hématologie, Centre Hospitalier Universitaire de Caen, Caen, France.
  • Service d'Hématologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.

ORCID-Profile: Tony Marchand, Cédric Pastoret, Charles Herbaux, Astrid Pavlosky, Aspasia Stamatoullas, Christer Nilsson

Zitieren

APA

Marchand, T., Pastoret, C., Damaj, G., Lebouvier, A., Herbaux, C., Moignet, A., Pavlosky, M., Pavlosky, A., Blouet, A., Eloit, M., Launay, V., Lebreton, P., Stamatoullas, A., Nilsson, C., Ochmann, M., Prola, J., & Lamy, T. (2024). Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia. British Journal of Haematology, 205(3), 915-923. https://doi.org/10.1111/bjh.19476

Vancouver

Marchand T, Pastoret C, Damaj G, Lebouvier A, Herbaux C, Moignet A, et al. Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia. British Journal of Haematology. 2024;205(3):915-923. doi:10.1111/bjh.19476

BibTeX
@article{Marchand2024,
  author = {Marchand, Tony and Pastoret, Cédric and Damaj, Gandhi and Lebouvier, Angélique and Herbaux, Charles and Moignet, Aline and Pavlosky, Miguel and Pavlosky, Astrid and Blouet, Anaise and Eloit, Martin and Launay, Vincent and Lebreton, Pierre and Stamatoullas, Aspasia and Nilsson, Christer and Ochmann, Marlène and Prola, Juliette and Lamy, Thierry},
  title = {Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {205},
  number = {3},
  pages = {915--923},
  doi = {10.1111/bjh.19476}
}
Kostenlos starten →